UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
UroGen Pharma Ltd. will present at TD Cowen’s 44th Annual Health Care Conference on March 4, 2024, at 1:30 PM ET. The presentation will focus on the company's innovative solutions for urothelial and specialty cancers. Investors can access the webcast on UroGen's website.
02/26/2024 - 08:00 AM
- Presentation March 4, 2024 at 1:30 PM ET -
PRINCETON, N.J. --(BUSINESS WIRE)--
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024 at 1:30pm EST.
TD Cowen 44th Annual Health Care Conference – March 4-6, 2024
Presentation: March 4, 2024 at 1:30 PM ET
Boston, MA
TD Cowen 44th Annual Health Care Conference (wsw.com)
A webcast from the conference will also be available via the Investors section of UroGen’s website, www.urogen.com . A replay of the webcast will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel . Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226631566/en/
INVESTOR CONTACT:
vincent.perrone@urogen.com
MEDIA CONTACT:
cindy.romano@urogen.com
Source: UroGen Pharma Ltd.
When will UroGen Pharma Ltd. present at TD Cowen’s 44th Annual Health Care Conference?
UroGen Pharma Ltd. will present on March 4, 2024, at 1:30 PM ET.
What is the focus of UroGen Pharma Ltd.'s presentation at the conference?
The presentation will focus on innovative solutions for urothelial and specialty cancers.
Where can investors access the webcast of the conference?
Investors can access the webcast on UroGen's website.
How long will the replay of the webcast be available?
The replay of the webcast will be available for approximately 90 days.
URGN Rankings
#2431 Ranked by Stock Gains
URGN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Israel
City
9 Hataasiya St
About URGN
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
